Ahmed I. Khodair

Prof. Ahmed I. Khodair

Kafrelsheikh University, Kafr ash Shaykh, Egypt
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Journal of Environmental Chemical Engineering
Verified
Journal Article
Closed access
EGEman A. Gendy
Eman A. Gendy
JIJerosha Ifthikar
Jerosha Ifthikar
JAJawad Ali
Jawad Ali
DODaniel T. Oyekunle
Daniel T. Oyekunle
ZEZouhair Elkhlifia
Zouhair Elkhlifia
ZCZhuqi Chen
Zhuqi Chen

1 January 1994 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AEAhmed A. El-Barbary
Ahmed A. El-Barbary
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
EPErik B. Pedersen
Erik B. Pedersen
CNClaus Nielsen
Claus Nielsen

1 November 1996 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
AAAm Al-Obaid
Am Al-Obaid
HEHussein El-Subbagh
Hussein El-Subbagh
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
MEMma Elmazar
Mma Elmazar
Certain series of 2-thiohydantoin derivatives, carrying various substituents at position 5 such as 5-bromo-2-thienylmethylene, 5-(2-carboxyphenylthio)-2-thienylmethylene and 2-methylene-4H-thieno[2,3-b][1]benzothiopyran-4-one, were evaluated for their antitumor activity. Compound 5-(5-bromo-2-thienylmethylene)-3-morpholinomethyl-2-(2,3,4,6 -tetra-O-acetyl -beta-D-glucopyranosylthio)hydantoin proved to possess a broad spectrum antitumor activity against a wide range of different human cell lines of nine tumor subpanels causing both cytostatic and cytotoxic effects, resulting in full panel median growth inhibition (GI50) and total growth inhibition (TGI), with a median lethal concentration (LC50) at 15.1, 41.7 and 83.2 microM, respectively. On the other hand, compound 5-(5-bromo-2-thienylmethylene)-2-thiohydantoin and compound 5-(5-bromo-2-thienylmethylene)-3-phenyl-2- (2,3,4,6-tetra-O-acetyl-beta-D-galactopyranosyl-thio)hydantoin showed potential selectivity against leukemia cell lines. Further derivatization of these compounds, deduced from the obtained tentative structure-activity relationships, may lead to more potent agents.

1 May 1998 in Tetrahedron
Verified
Journal Article
Closed access
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
PBPhilippe Bertrand
Philippe Bertrand

1 December 2019 in Carbohydrate Research
Verified
Journal Article
Closed access
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
MAMona A. Alsafi
Mona A. Alsafi
MNMohamed S. Nafie
Mohamed S. Nafie

16 December 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Ahmed I. KhodairAhmed I. Khodair
Ahmed I. Khodair
SESalwa M. El-Hallouty
Salwa M. El-Hallouty
BCBrittnee Cagle-White
Brittnee Cagle-White
MAMay H. Abdel Aziz
May H. Abdel Aziz
MHMahmoud Kh. Hanafy
Mahmoud Kh. Hanafy
SKShaymaa E. Kassab
Shaymaa E. Kassab